Deacetylasperulosidic Acid Methyl Ester Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis by Suppressing Inflammation and Modulating Gut Microbiota Authors: Li Chen, Chunyan Chen, Qixiang Chen, Ting Jiang, Lingli Zheng, Rong Tang, Cheng Wang Published: 2025 ABSTRACT AbstractLiver fibrosis is an excessive wound-healing response triggered by chronic liver injury. It may eventually progress to cirrhosis, liver failure or liver cancer. Currently, there are no effective therapeutic strategies available. Deacetylasperulosidic acid methyl ester (DAM), a natural iridoid compound derived from Rubiaceae plants, possesses potential anti-inflammatory activity. However, its role in liver fibrosis and the underlying mechanisms remain unclear. Given the critical involvement of inflammation and gut microbiota dysbiosis in the development of liver fibrosis, this study aimed to investigate whether DAM could ameliorate liver fibrosis by modulating hepatic inflammation and intestinal dysbiosis. Using a carbon tetrachloride (CCl4)-induced liver fibrosis model in mice, we evaluated DAM’s effects via histopathology, serum biochemical assays, liver fibrosis marker detection, intestinal barrier analysis and 16S rRNA gene sequencing. DAM treatment significantly alleviated hepatic histopathological damage, reduced serum levels of ALT, AST and γ-GT, inhibited hepatic collagen deposition (HA, LN, IV-C and PC Ⅲ) and reduced the expression of the fibrotic markers α-SMA and Col1a1. Furthermore, DAM markedly inhibited the hepatic expression of the pro-inflammatory cytokines TNF-α, IL-1β and IL-6, demonstrating its anti-inflammatory properties. DAM also attenuated intestinal structural damage, enhanced the expression of tight junction proteins Claudin-1, ZO-1 and Occludin, and improved intestinal barrier integrity, thereby reducing endotoxin translocation. 16S rRNA gene sequencing further revealed that DAM improved CCl4-induced gut microbiota dysbiosis by reducing the abundance of pro-inflammatory genera such as Faecalibaculum and Dubosiella, thereby contributing to the restoration of microbial homeostasis. Collectively, DAM effectively ameliorates CCl4-induced liver fibrosis by modulating hepatic inflammation and gut microbiota dysbiosis and may serve as a promising candidate for the prevention and treatment of liver fibrosis.Keywords: Deacetylasperulosidic acid methyl ester, Liver fibrosis, Inflammation, Gut microbiota, Carbon tetrachloride, Hepatic stellate cells Introduction Liver fibrosis is an excessive wound-healing response to chronic liver injury [1]. It is characterized by the sustained activation of hepatic stellate cells (HSCs) and the abnormal accumulation of extracellular matrix (ECM) components, such as collagen [2]. This pathological process can progress to liver cirrhosis, hepatic failure or hepatocellular carcinoma, posing a serious threat to human health [3, 4]. Current clinical treatment strategies for liver fibrosis focus primarily on controlling the underlying causes and developing drugs that target specific molecular pathways [4, 5]. However, existing therapies are generally limited by suboptimal efficacy, significant side effects and an inability to reverse established fibrosis [6, 7]. Therefore, elucidating the key mechanisms underlying liver fibrogenesis and developing safe and effective therapeutic approaches remain critical challenges and priorities in hepatology. Inflammatory responses play a central role in the initiation, progression and persistence of liver fibrosis [8]. Chronic liver injury continuously activates innate immune cells, promoting the release of large quantities of pro-inflammatory cytokines and chemokines, which in turn recruit peripheral inflammatory cells to infiltrate the liver and establish a chronic inflammatory microenvironment [9]. During this process, inflammatory signaling not only directly damages hepatic parenchymal cells but also induces the transdifferentiation of quiescent HSCs into myofibroblast-like cells, which become the primary source of ECM production [10]. Furthermore, activated HSCs can amplify the inflammatory response by secreting additional pro-inflammatory and pro-fibrotic mediators, thus creating a cycle of inflammation and fibrosis [11]. Therefore, effectively suppressing excessive hepatic inflammation is considered a key therapeutic strategy for halting or even reversing the fibrotic process. In recent years, accumulating evidence has emphasized the important regulatory function of the gut microbiota and its metabolites in liver fibrosis [12, 13]. Dysbiosis of the gut microbiota, alongside impaired intestinal barrier function, can result in the translocation of bacterial products [14]. These products are recognized by hepatic immune cells, such as Kupffer cells, which subsequently activate inflammatory pathways via Toll-like receptors [15]. Increasing studies have demonstrated that patients with liver fibrosis commonly exhibit characteristic alterations in the composition of their gut microbiota, and the degree of dysbiosis is closely associated with the severity of fibrosis [16, 17]. Given the plasticity of the gut microbiota, strategies targeting microbial composition and function, restoring intestinal barrier integrity and interrupting inflammation-related signaling cascades have emerged as promising approaches to preventing and treating liver fibrosis. Natural products have attracted considerable attention in the field of liver fibrosis therapy due to their multi-target regulatory properties, low toxicity and good biocompatibility [18, 19]. In particular, active compounds derived from traditional Chinese medicine have been widely reported to exhibit anti-inflammatory, antioxidant, immunomodulatory and gut microbiota-regulating activities, making them a valuable resource for the development of antifibrotic agents [20–22]. Notably, deacetylasperulosidic acid methyl ester (DAM) is an iridoid compound isolated from Rubiaceae plants, such as Hedyotis diffusa and Morinda officinalis. Previous studies have demonstrated that DAM exhibits hypoglycemic and anti-osteoporotic activities [23, 24]. Moreover, based on the pharmacological profiles of structurally related iridoid compounds, DAM may also exhibit anti-inflammatory and antioxidant properties, thereby suggesting its potential utility in the prevention and management of various chronic diseases. However, its effects and underlying mechanisms in liver fibrosis remain unknown. Given the pivotal roles of inflammatory responses and gut microbiota dysbiosis in the pathogenesis of liver fibrosis, this study aims to determine whether DAM can ameliorate CCl4-induced liver fibrosis by concurrently modulating hepatic inflammation and intestinal microbiota imbalance. The findings of this work not only provide novel mechanistic insights into the pathogenesis of liver fibrosis but also lay a theoretical foundation for the therapeutic development of DAM and other natural products. Materials and Methods Materials The experimental materials used in this study are listed in Table 1. Table 1Manufacturer and item number of the experimental materialsMaterialsManufacturerItem numberDeacetylasperulosidic acid methyl esterMust Bio-Technology Co., Ltd., Chengdu, China24120325ColchicineMust Bio-Technology Co., Ltd., Chengdu, China24102517Carbon tetrachlorideYien Chemical Technology Co., Ltd., Shanghai, ChinaRH631559Olive oilYien Chemical Technology Co., Ltd., Shanghai, ChinaRH4708684% paraformaldehydeLabgic Technology Co., Ltd., Beijing, China23257838BCA Protein Quantification KitServicebio technology Co., Ltd., Wuhan, ChinaCR2405090Hyaluronic acid (HA) ELISA KitMeimian Industrial Co., Ltd., Jiangsu, ChinaMM-0514M1Laminin (LN) ELISA KitMeimian Industrial Co., Ltd., Jiangsu, ChinaMM-0161M1Type III procollagen peptide (PC III) ELISA KitMeimian Industrial Co., Ltd., Jiangsu, ChinaMM-0033M1Collagen type IV (IV-C) ELISA KitMeimian Industrial Co., Ltd., Jiangsu, ChinaMM-0297M1Lipopolysaccharides (LPS) ELISA KitMeimian Industrial Co., Ltd., Jiangsu, ChinaMM-45080M1RNA extraction solutionServicebio Technology Co., Ltd., Wuhan, ChinaG3013Chloroform substitutewereServicebio Technology Co., Ltd., Wuhan, ChinaG30145 × SweScript All-in-One RT SuperMix for qPCRServicebio Technology Co., Ltd., Wuhan, ChinaG33372 × Universal Blue SYBR Green qPCR Master MixServicebio Technology Co., Ltd., Wuhan, ChinaG3326Primer sequenceServicebio Technology Co., Ltd., Wuhan, ChinaNA Manufacturer and item number of the experimental materials Animals and Experimental Protocols C57BL/6 J male mice aged 8 weeks and weighed 18–22 g (Chengdu Yaokang Biotechnology Co., Ltd., Chengdu, China) were used for this study. All animals were housed in a specific pathogen-free environment under controlled conditions of temperature, humidity and light/dark cycle. The mice had ad libitum access to food and water. Animal procedures were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals, as established by Chengdu Medical College. All protocols were approved by the Institutional Animal Care and Use Committee of Chengdu Medical College (Permit number: SYXK2020-0196). The experimental protocol is shown in Fig. 1. Overview of the experimental protocol Following a seven-day acclimatization period, the 36 mice were randomly divided into six experimental groups (n = 6 per group): (1) Control group, (2) CCl4 group, (3) CCl4 + 10 mg/kg DAM group, (4) CCl4 + 20 mg/kg DAM, (5) CCl4 + 40 mg/kg DAM, (6) CCl4 + 0.1 mg/kg colchicine group. Specifically, the liver fibrosis model was established by intraperitoneal injection of 10% CCl4 in olive oil three times per week for five weeks, as described in previous studies [25, 26]. The control group mice received intraperitoneal injections of olive oil. From the third week onwards, the treatment groups received DAM or colchicine at the designated doses via daily intragastric administration, while the remaining mice were given an equal volume of normal saline. At the end of the experiment, all the mice were humanely euthanized and serum, liver, colon and fecal samples were collected for subsequent analyses and stored appropriately. Histopathological Analysis The liver and colon tissues were promptly collected and fixed in 4% paraformaldehyde for 24 h. Following fixation, the samples were dehydrated, embedded in paraffin wax and sectioned into thin slices. The paraffin-embedded tissue sections were deparaffinized, rehydrated and cut to a thickness of 4 μm. Subsequently, the slides were stained using hematoxylin and eosin (HE), Sirius red and Masson's trichrome methods. After staining, the sections were dehydrated, mounted with coverslips and examined under a digital pathology slide scanner to acquire images. The morphometric parameters, including villus height, villus width and crypt depth of the colon, were quantified using Image-Pro Plus 6.0 software. Serum Biochemical Indexes Detection Blood samples were centrifuged at 4 °C for 10 min at 2000 rpm to separate the serum. The levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transpeptidase (γ-GT) in the serum were quantified using a fully automated biochemical analyzer (Mindray BS360S, China), in accordance with the manufacturer's instructions. Liver Biochemical Indexes Detection The liver tissue was weighed and homogenized in nine volumes of the appropriate lysis buffer. This was then centrifugation at 3500 rpm for 10 min. The resulting supernatant was used to prepare a 10% tissue homogenate. The concentrations of HA, LN, PC III and IV-C were quantified in order to assess the degree of liver fibrosis using ELISA kits according to the manufacturer's instructions. Immunohistochemistry Analysis First, formalin-fixed, paraffin-embedded liver sections were subjected to deparaffinization and hydration through a graded series of xylene and ethanol. Antigen retrieval was then performed using citrate buffer (pH 6.0) under heating conditions. To block endogenous peroxidase activity, the sections were treated with 3% hydrogen peroxide in the absence of light for 0.25 h. After washing, the sections were incubated with the appropriate primary antibody at 4 °C overnight. The following day, the slides were rinsed with PBS, after which they were incubation with a secondary antibody at 37℃ for 0.5 h. Immunoreactivity was detected using a DAB substrate solution and nuclei were counterstained with hematoxylin. Images were captured using a high-resolution digital slide scanner for further analysis. Analysis of Gut Microbial Composition by 16S rRNA Gene Sequencing Total genomic DNA was isolated from mouse fecal samples using a commercially available extraction kit, following the supplier's protocol. The integrity and concentration of DNA were evaluated using 1.8% agarose gel electrophoresis and a microplate spectrophotometer. The nearly full-length bacterial 16S rRNA gene was amplified using the universal primers 27F (5′-AGRGTTTGATYNTGGCTCAG-3′) and 1492R (5′-TASGGHTACCTTGTTASGACTT-3′). The PCR amplicons were visualized on a 2% agarose gel, excised and purified using the Monarch DNA Gel Extraction Kit. DNA concentrations were measured using the Qubit 4.0 fluorometer. Subsequently, equal molar quantities of qualified PCR products from each sample were pooled for SMRTbell library construction using the SMRTbell Template Prep Kit. The size and concentration of the final library were assessed with Qubit 4.0 and Agilent 2100 Bioanalyzer, respectively. High-throughput sequencing was performed on the PacBio Sequel II system using SMRT Cell 8 M technology. The raw data were processed in BAM format using SMRT Link v10.1 to remove sequencing adapters via Lima, followed by quality filtering with Cutadapt and chimera elimination using UCHIME. To profile the microbial community, operational taxonomic units were defined at a 97% sequence similarity threshold using USEARCH v11.0. Taxonomic classification was performed using the SILVA rRNA gene database as a reference. To ensure comparability among samples, sequence counts were rarefied to the minimum sequencing depth observed, and relative abundance normalization was applied prior to downstream analyses. Subsequent bioinformatic analyses included the assessment of microbial composition, α- diversity and β-diversity metrics, intergroup differential abundance analysis, functional pathway prediction and microbial correlation network construction. Real-Time Quantitative PCR (RT-qPCR) Analysis Liver tissue samples were subjected to total RNA isolation using a commercial RNA extraction solution supplemented with a chloroform alternative. The purity and concentration of the isolated RNA were evaluated spectrophotometrically using a NanoDrop 2000. cDNA was synthesized from the purified RNA via reverse transcription using the 5 × SweScript All-in-One SuperMix for qPCR (One-Step gDNA Remover) according to the manufacturer’s protocol. RT-qRCR was then performed using a two-step amplification program: an initial denaturation at 95 °C for 30 s, followed by 40 amplification cycles consisting of denaturation at 95 °C for 15 s and annealing/extension at 60 °C for 30 s. The primer sequences were listed in Table 2. Relative mRNA expression levels were calculated using the 2−ΔΔCT method, ensuring amplification of a single product during each PCR run. Table 2Primers used for RT-qPCR in this studyGeneForward primer (5'-3')Reverse primer (5'-3')α-SMAGTACCACCATGTACCCAGGCGAAGGTAGACAGCGAAGCCACol1a1CTCCCAGAACATCACCTATCACTGGAGGTCTTGGTGGTTTTGTATTTNF-αGACAGTGACCTGGACTGTGGTGAGACAGAGGCAACCTGACIL-1βGAAGAAGAGCCCATCCTCTGTCATCTCGGAGCCTGTAGTGIL-6CCCCAATTTCCAATGCTCTCCCGCACTAGGTTTGCCGAGTAGAPDHCCTCGTCCCGTAGACAAAATGTGAGGTCAATGAAGGGGTCGT Primers used for RT-qPCR in this study Immunofluorescence Analysis Colon specimens preserved by fixation in 4% paraformaldehyde and embedded in paraffin were subjected to deparaffinization followed by sequential rehydration through descending concentrations of ethanol. Subsequently, antigen retrieval was carried out using a pH 7.4 buffer to enhance epitope accessibility. The sections were then incubated overnight at 4 °C with primary antibodies specific for Claudin-1, Occludin and ZO-1. All steps were conducted under light-protected conditions to preserve fluorescence integrity. The following day, after washing, the sections were incubated with fluorophore-conjugated secondary antibodies for 50 min at ambient temperature in the dark. Nuclei were labeled with DAPI to facilitate cellular localization and an autofluorescence quenching solution was applied to minimize background signal. Finally, the stained samples were visualized and digitally recorded using a Pannoramic MIDI scanner for subsequent analysis. Statistical Analysis Data analysis was performed using SPSS software (Version 25.0, SPSS Inc., Chicago, IL, USA). Results are expressed as the mean ± standard deviation (SD). Graphs were created using GraphPad Prism 8.0 software. Differences among multiple groups were assessed using one-way analysis of variance (ANOVA). When the assumption of homogeneity of variance was met, the post-hoc test of Fisher’s Least Significant Difference (LSD) was applied for multiple comparisons. Otherwise, the Games-Howell test was used. A p-value of less than 0.05 (p < 0.05) was considered statistically significant, corresponding to a 95% confidence level. Results DAM Improves Histopathological Features and Serum Biochemical Markers of Liver Injury As depicted in Fig. 2a, histopathological evaluation using HE staining revealed that the hepatic lobular architecture of liver sections from the control group remained intact, with well-aligned hepatocyte cords, uniformly arranged hepatocytes and no observable inflammatory infiltration or fibrotic lesions. In contrast, CCl4-induced mice exhibited pronounced structural disruption characterized by lobular disarray, widespread hepatocyte necrosis and dense inflammatory cell infiltration within the hepatic parenchyma. Remarkably, DAM treatment alleviated these histopathological damages in a dose-dependent manner. Protective effects of DAM on liver histopathology and serum biochemical markers in CCl4-induced liver fibrosis in mice. a Representative images of liver sections stained with HE (× 100 and × 200). b Serum levels of ALT, AST and γ-GT (n = 6). ###p < 0.001 represent compared with control group. **p < 0.01, ***p < 0.001 represent compared with CCl4 group Consistent with the histological improvements, serum biochemical assessments (Fig. 2b) provided further evidence of the hepatoprotective action of DAM. CCl4 treatment led to a substantial elevation in serum transaminases ALT, AST and γ-GT, reflecting significant hepatic injury and compromised membrane integrity (p < 0.001). Notably, treatment with intermediate and high doses of DAM (20 and 40 mg/kg) resulted in a statistically significant reduction in these enzyme levels (p < 0.01). This suggests that DAM protects against CCl4-induced hepatocellular damage and enhances liver function overall. DAM Alleviates Collagen Deposition and Fibrotic Remodeling in Liver Tissue As illustrated in Fig. 3a, Masson and Sirius red staining techniques were employed to assess hepatic collagen deposition. Collagen fibres were visualized as blue and red, respectively. Liver tissues from the control group exhibited negligible collagen presence, indicating normal ECM distribution. In contrast, substantial collagen accumulation was evident in liver sections from the CCl4-treated group, reflecting the development of advanced liver fibrosis. Interestingly, administration of DAM at doses of 20 and 40 mg/kg resulted in a significant decrease in fibrotic areas, demonstrating a clear dose–response trend and underscoring the compound’s potential anti-fibrotic efficacy (Fig. 3b and c). DAM attenuates collagen deposition induced by CCl4 in mouse liver tissue. a Representative images of Masson and Sirius red staining of liver sections (× 100 and × 200). b-c Quantitative analysis of fibrotic area based on Masson and Sirius red staining (n = 3). d-g Hepatic levels of fibrosis-related markers, including HA, LN, IV-C and PC III (n = 6). ##p < 0.01, ###p < 0.001 represent compared with control group. *p < 0.05, **p < 0.01, ***p < 0.001 represent compared with CCl4 group Complementary to histological observations, the quantitative analysis of biochemical indicators related to liver fibrosis provided further evidence of the protective role of DAM (Fig. 3d, e, f and g). CCl4 significantly increased hepatic levels of HA, LN, PC III and IV-C, which is consistent with active fibrogenesis. Treatment with DAM at doses of 20 and 40 mg/kg effectively suppressed these fibrotic markers in a concentration-dependent manner, thereby reinforcing its inhibitory effect on liver fibrogenesis and ECM remodeling. DAM Inhibits HSC Activation To evaluate the impact of DAM on HSC activation, the expression levels of α-SMA and Col1a1, two widely recognized markers of activated HSCs, were analyzed using immunohistochemistry (Fig. 4a). Compared to the control group, CCl4 administration resulted in significant upregulation of both proteins, with α-SMA and Col1a1 increasing by approximately 4.8-fold and 6.3-fold, respectively, indicating robust fibrogenic activity. Notably, treatment with DAM (20 and 40 mg/kg) significantly attenuated the expression of both markers, reflecting suppressed HSC activation (Fig. 4b and c). Consistent with the immunohistochemical results, RT-qPCR analysis (Fig. 4d and e) confirmed a significant reduction in α-SMA and Col1a1 mRNA expression levels following DAM treatment, indicating transcriptional downregulation of these fibrosis-related genes. Taken together, these results suggest that DAM primarily exerts its anti-fibrotic effects by inhibiting HSC activation and collagen production, thereby disrupting a critical step in the fibrogenesis process. DAM suppresses HSC activation and collagen production in CCl4-induced liver fibrosis. a Representative immunohistochemical staining of α-SMA and Col1a1 in liver tissues (× 200 and × 400). b-c Quantitative analysis of α-SMA and Col1a1 immunostaining scores (n = 3). d-e The mRNA expressions of α-SMA and Col1a1 (n = 6). ###p < 0.001 represent compared with control group. *p < 0.05, **p < 0.01, ***p < 0.001 represent compared with CCl4 group DAM Reduces Systemic Endotoxemia and Hepatic Inflammatory Cytokine Expression To determine whether DAM mitigates bacterial translocation, the serum levels of LPS (a marker of endotoxemia) were quantified. As illustrated in Fig. 5a, CCl4 treatment significantly increased circulating LPS concentrations compared to the control group, indicating compromised intestinal barrier function and systemic microbial component influx. In contrast, the administration of DAM (10, 20 and 40 mg/kg) significantly reduced serum LPS levels relative to the CCl4 group. This suggests that DAM helps to restore mucosal barrier integrity and limits the leakage of bacterial product. In parallel, the hepatic expression of key inflammatory mediators was examined to assess the inflammatory response associated with liver fibrosis. As shown in Fig. 5b, c and d, levels of TNF-α, IL-1β and IL-6 were markedly increased following CCl4 exposure. However, DAM administration (20 and 40 mg/kg) led to a significant downregulation of these pro-inflammatory cytokines, indicating a robust anti-inflammatory effect. Overall, these data demonstrate that DAM attenuates both bacterial translocation and inflammation associated with fibrogenesis in the liver. DAM attenuates systemic endotoxemia and hepatic inflammation. a Serum LPS levels (n = 6). b-d The mRNA expressions of TNF-α, IL-1β and IL-6 (n = 6). ###p < 0.001 represent compared with control group. ***p < 0.001 represent compared with CCl4 group DAM Modulates the Overall Diversity and Community Structure of Gut Microbiota As illustrated in Fig. 6a, CCl4-induced liver fibrosis resulted in a substantial decrease in gut microbial diversity, as demonstrated by the lower Shannon index in comparison with the control group. This loss of α-diversity reflects reduced microbial richness and evenness in the model mice. Notably, administration of DAM significantly increased the Shannon index, indicating a partial restoration of microbial diversity and suggesting a protective role in maintaining gut ecological balance. To further explore global shifts in microbial community composition, principal component analysis (PCA) was conducted. The results (Fig. 6b) showed that the CCl4 group clustered distinctly apart from the control group, whereas samples from the DAM-treated group clustered closer to the control group. This implies that DAM modulates the overall microbial architecture. DAM modulates gut microbiota diversity and composition. a Alpha diversity analysis, including Chao1 richness, Shannon diversity, and Simpson evenness indices, demonstrated changes in microbial diversity among groups (n = 6). b-d Beta diversity was assessed using PCA, PLS-DA and NMDS, revealing distinct clustering of microbial communities (n = 6). e Relative abundance of gut microbiota at the phylum level (n = 6). (f) Representative gut microbiota at the phylum level (n = 6). g The ratio of Firmicutes to Bacteroidetes (n = 6). A: Control group; B: CCl4 group; C: 40 mg/kg DAM group. ##p < 0.01, ###p < 0.001 represent compared with control group. *p < 0.05 represent compared with CCl4 group In addition, partial least squares discriminant analysis (PLS-DA) (Fig. 6c) further confirmed clear discrimination among the three groups at the species level, reinforcing the finding that DAM restructured the microbial community composition. Moreover, non-metric multidimensional scaling (NMDS) based on Bray–Curtis distance (Fig. 6d) revealed comparable group segregation patterns, with the CCl4 group diverging significantly from the control group and the DAM group exhibiting a shift towards microbial communities that resemble those of healthy mice. These results support the conclusion that DAM treatment ameliorates CCl4-induced gut microbiota dysbiosis. Collectively, these findings indicate that CCl4-induced liver fibrosis significantly disrupts gut microbial diversity and composition, whereas DAM administration helps to restore microbial homeostasis and structural integrity. DAM Reshapes the Taxonomic Composition of Gut Microbiota in Fibrotic Mice At the phylum level, CCl4 exposure significantly altered the intestinal microbial profile, characterized by a notable increase in Firmicutes and Actinobacteriota, alongside a considerable reduction in Bacteroidota (Fig. 6e and f). These compositional shifts reflect microbial dysbiosis commonly associated with liver fibrosis. Notably, DAM administration markedly reduced the Firmicutes-to-Bacteroidota (F/B) ratio, a widely used indicator of gut microbial imbalance, while restoring the relative abundance of these major phyla, suggesting a robust corrective effect on dysbiosis (Fig. 6g). Collectively, these findings highlight the important regulatory role of DAM in maintaining gut microbial equilibrium in fibrotic mice. At the genus level, specific bacterial populations exhibited dramatic fluctuations. Specifically, Lactobacillus, Faecalibaculum, and Dubosiella were significantly enriched, whereas uncultured_Bacteroidales_bacterium was notably reduced compared to the control group. Treatment with DAM effectively reversed these shifts in the microbial population, suggesting a potential role for DAM in restoring gut microbiota homeostasis (Fig. 7a, b and c). DAM ameliorates CCl4-induced gut microbiota dysbiosis at the genus level. a-b Representative taxonomic profiles illustrating the composition of gut microbiota at the genus level across different groups (n = 6). c Comparison of the relative abundances of dominant bacterial genera among the treatment groups (n = 6). d LEfSe identified key taxa differentially enriched between groups. e LDA scores highlight the most significantly altered genera contributing to group differentiation. A: Control group; B: CCl4 group; C: 40 mg/kg DAM group. ##p < 0.01, ###p < 0.001 represent compared with control group. *p < 0.05, **p < 0.01, ***p < 0.001 represent compared with CCl4 group To further identify the key microbial taxa contributing to group-specific differences, linear discriminant analysis (LDA) was performed. As shown in Fig. 7d and e, LDA scores revealed distinct microbial signatures among the control, CCl4 and DAM-treated groups, with 15, 10 and 5 dominant taxa uniquely enriched in each group, respectively. These findings suggest that liver fibrosis causes significant taxonomic changes, favouring potentially pathogenic bacteria and suppressing beneficial microbes. DAM may ameliorate liver fibrosis by modulating these microbial populations and re-establishing intestinal microbial homeostasis, thereby exerting microbiota-dependent therapeutic effects. Functional Prediction and Microbiota-Host Correlation Analysis Functional differences and alterations in the metabolic pathways of microbial communities among different groups were analyzed using the KEGG and COG databases. As shown in Fig. 8a and b, the predominant microbial functional pathways in the CCl4 group were enriched in carbohydrate metabolism, nucleotide metabolism and translation, as well as ribosomal structure and biogenesis. In contrast, DAM treatment shifted the dominant pathways towards global and overview maps, amino acid metabolism and cell wall/membrane/envelope biogenesis. These changes suggest that DAM may exert its therapeutic effects, at least in part, by modulating the functional composition of the gut microbiota, thereby influencing microbial metabolic activities that are closely related to liver homeostasis and fibrosis progression. Functional prediction of gut microbiota and correlation analysis. a Predicted functional profiles of gut microbiota based on KEGG pathways. b Predicted microbial functions inferred from the COG database. c CCA illustrating the relationship between microbial community structure and environmental variables. d Heatmap displaying Pearson correlation coefficients between representative gut microbial genera and serum/liver biochemical parameters in mice. A: Control group; B: CCl4 group; C: 40 mg/kg DAM group.#p < 0.05, ##p < 0.01, ###p < 0.001 Subsequently, redundancy analysis (RDA) was performed to evaluate the correlations between the gut microbiota and serum/liver biochemical parameters in mice. As shown in Fig. 8c, strong associations were observed between microbial community composition and several biochemical indicators. This provides important evidence for understanding the potential influence of specific bacterial genera on the hepatic physiology of the host. In addition, the heatmap showing the correlations between the gut microbiota and the biochemical parameters (Fig. 8d) revealed that there were significant relationships between specific genera and the liver-related markers. For example, Bacteroides showed significant positive correlations with multiple markers of liver injury and inflammation, including Col1a1, IV-C, AST, γ-GT and LPS. Similarly, Dubosiella exhibited positive correlations with HA, Col1a1, ALT, IV-C, PC III, α-SMA, AST, LN and TNF-α, suggesting its potential role in activating fibrotic and inflammatory processes. Conversely, Odoribacter exhibited significant negative correlations with Col1a1, ALT, IV-C, PC III, α-SMA, AST, LN, LPS, IL-1β, IL-6 and TNF-α, and Muribaculum was negatively associated with Col1a1, ALT, IV-C, PC III, AST and LN, indicating that these genera may play a protective role in suppressing hepatic inflammation and fibrosis progression. Collectively, these findings imply that DAM may exert its hepatoprotective effects by modulating the composition of the gut microbiota and its correlation with host biochemical parameters, thereby influencing hepatic inflammatory responses and the extent of fibrosis. DAM Improves Colonic Mucosal Morphology in Fibrotic Mice Given that impairment of the intestinal mucosal barrier is a hallmark pathological alteration associated with liver fibrosis, histopathological evaluation of colon tissues was performed via HE staining. As illustrated in Fig. 9a, the intestinal architecture of the control group remained intact, with well-organized ileal layers, uniform distribution of villus and crypts, and normal morphology of epithelial cells. By contrast, mice subjected to CCl4-induced liver fibrosis exhibited significant colonic epithelial damage, including pronounced cellular swelling, structural disorganization and villus fragmentation. Treatment with DAM at doses of 10, 20 and 40 mg/kg significantly reduced these pathological changes. DAM administration led to decreased inflammatory cell infiltration, preservation of epithelial integrity and re-establishment of villus morphology characterized by enhanced structural alignment and regularity. Furthermore, DAM significantly increased key morphological indices of intestinal integrity, such as villus height, villus width and crypt depth (Fig. 9b, c and d). Taken together, these results underscore DAM’s ability to attenuate intestinal mucosal injury in cases of CCl4-induced liver fibrosis, thus supporting its protective role in maintaining gut barrier function. Protective effect of DAM on CCl4-induced intestinal epithelial barrier damage. a Representative HE staining images of colon tissue (× 40 and × 200). b-d Quantitative of villus height, villus width and crypt depth among groups (n = 6). ###p < 0.001 represent compared with control group. *p < 0.05, **p < 0.01, ***p < 0.001 represent compared with CCl4 group DAM Enhances Intestinal Barrier Function by Upregulating TJ Protein Expression To gain deeper insight into the regulatory role of DAM in preserving the integrity of the intestinal barrier, immunofluorescence staining was used to assess the expression of representative tight junction (TJ) proteins, including Claudin-1, ZO-1 and Occludin. As shown in Fig. 10a, CCl4-induced liver fibrosis resulted in a significant decrease in the fluorescence intensity of all three TJ markers, indicating impaired epithelial barrier integrity. Notably, DAM administration significantly restored the expression of Claudin-1, ZO-1 and Occludin relative to the CCl4 group (Fig. 10b, c and d). These results imply that DAM protects against epithelial barrier dysfunction by reinforcing TJ protein expression, thereby improving intestinal barrier function in fibrotic conditions. DAM enhances the expression of TJ proteins in colon tissue. a Representative immunofluorescence staining images of Claudin-1, ZO-1 and Occludin in colon sections (× 200). b Quantitative analysis of fluorescence intensity for Claudin-1, ZO-1 and Occludin (n = 3). ###p < 0.001 represent compared with control group. **p < 0.01, ***p < 0.001 represent compared with CCl4 group Discussion Liver fibrosis represents a common pathological consequence of diverse chronic liver diseases, including viral hepatitis, alcoholic liver disease and metabolic-associated fatty liver disease [3, 27]. It is characterized by excessive ECM accumulation, which progressively remodels the hepatic lobular architecture, impaired liver function and ultimately results in cirrhosis and hepatocellular carcinoma, posing a major global health burden [28]. To date, no specific and effective anti-fibrotic drugs have been approved, and current clinical management primarily aims at controlling the underlying etiology [6, 7]. This highlights an urgent need for the development of safe and effective therapeutic strategies. In this regard, natural products have attracted increasing attention owing to their multitarget properties and relatively low toxicity [19]. DAM, a natural iridoid compound derived from plants of the Rubiaceae family, remains insufficiently studied, and its pharmacological potential, particularly in the context of liver fibrosis, has not been fully elucidated. In the present study, we systematically evaluated the anti-fibrotic effects of DAM in a CCl4-induced mouse model and explored its potential mechanisms, thereby providing experimental evidence to support its development as a novel therapeutic candidate for liver fibrosis. This study employed a CCl4-induced mouse model of liver fibrosis, which is widely used for the screening of anti-fibrotic agents and mechanistic studies due to its reproducibility, stability and close resemblance to the pathological progression of human liver fibrosis [29]. Its hepatotoxic metabolites, generated by cytochrome P450 enzymes, trigger oxidative stress, hepatocyte necrosis, and inflammation, culminating in fibrogenesis [30, 31]. In our study, CCl4 administration induced pronounced hepatic structural disruption, inflammatory cell infiltration, and collagen deposition, accompanied by significant elevations in serum ALT, AST and γ-GT levels, indicating hepatocellular injury and cholestasis. These findings are consistent with our previous observations [25, 32]. Importantly, DAM treatment markedly ameliorated the histopathological alterations induced by CCl4 and significantly reduced serum liver enzyme levels, supporting its hepatoprotective potential. A hallmark of liver fibrosis is the activation of hepatic stellate cells (HSCs), which transdifferentiate into myofibroblast-like cells and drive ECM accumulation [33, 34]. α-SMA and Col1a1 are well-established markers of HSC activation, and their expression levels are positively correlated with the severity of liver fibrosis [2, 35]. In this study, treatment with DAM significantly reduced the levels of multiple fibrosis-related biomarkers in liver tissue, including HA, LN, and IV-C and PC III, and decreased the positive staining area in both Masson and Sirius red staining, indicating an inhibition of collagen deposition. Furthermore, DAM markedly downregulated the expression of α-SMA and Col1a1 at both transcriptional and protein levels, suggesting effective suppression of HSC activation. Chronic inflammation is another critical driver of fibrosis [8]. Endotoxin leakage from the gut, primarily LPS, activates Kupffer cells through TLR4 and induces pro-inflammatory cytokine release, perpetuating a positive feedback loop between inflammation and fibrogenesis [36, 37]. In this study, CCl4-treated mice developed systemic endotoxemia and robust hepatic inflammatory responses. DAM significantly reduced circulating LPS and suppressed hepatic TNF-α, IL-1β and IL-6 expression, indicating potent anti-inflammatory effects. Mechanistically, these findings suggest that DAM may interfere with the TLR4/NF-κB axis, thereby disrupting the inflammatory crosstalk between Kupffer cells and HSCs. Moreover, since fibrosis is frequently associated with oxidative stress, the Nrf2 pathway, a central regulator of antioxidant defense, represents another plausible target. Given that certain iridoid compounds activate Nrf2, DAM may confer dual protection by simultaneously inhibiting TLR4/NF-κB-mediated inflammation and activating Nrf2-driven antioxidant responses. In recent years, increasing evidence has highlighted the contribution of gut microbiota dysbiosis to the development of liver fibrosis [38]. The gut microbiota modulates immune responses, metabolite synthesis and intestinal barrier integrity, thereby shaping the “gut-liver axis” that critically influences fibrogenesis [15]. In this study, 16S rRNA sequencing revealed that CCl4 administration markedly altered microbial composition, characterized by an increased relative abundance of Firmicutes and Actinobacteriota and a concomitant reduction of Bacteroidota, resulting in an elevated F/B ratio. This ratio is widely recognized as a marker of microbial metabolic status and pro-inflammatory potential [39]. Although certain Firmicutes members (e.g. lactic acid bacteria) may exert probiotic effects, their enrichment under hepatic injury is often associated with increased LPS and secondary bile acids production, thereby aggravating inflammation [40, 41]. In contrast, Bacteroidota serve as major producers of short-chain fatty acids (SCFAs), such as acetate and butyrate, which regulate immune homeostasis and suppress HSC activation through GPR41/43 signaling and NF-κB inhibition [42, 43]. DAM treatment significantly reduced the F/B ratio and restored Bacteroidota abundance, indicating its capacity to reestablish microbial metabolic balance and promote an anti-inflammatory milieu. At the genus level, CCl4 treatment notably enriched Faecalibaculum and Dubosiella, whereas DAM effectively inhibited their abnormal proliferation. Faecalibaculum, a lactic acid-producing genus within Firmicutes, although transiently enriched in some metabolic disease models, is commonly associated with pro-inflammatory responses, oxidative stress and intestinal barrier disruption in liver diseases, particularly fibrosis [44, 45]. DAM-mediated suppression of Faecalibaculum may help alleviate oxidative stress and immune hyperactivation, thereby mitigating liver fibrosis. Dubosiella, a recently characterized genus within Actinobacteriota, has been linked to obesity, hepatitis and non-alcoholic fatty liver disease [46, 47]. Despite its relatively low metabolic activity, Dubosiella produces components that stimulate immune activation and promote intestinal barrier dysfunction and inflammatory cytokine upregulation [48, 49]. The significant reduction of Dubosiella by DAM indicates its potential to alleviate gut inflammation and contribute to the maintenance of gut-liver axis homeostasis. Intestinal barrier integrity represents a central checkpoint in gut-liver crosstalk [12, 50]. Consistent with previous reports, CCl4 induced villus atrophy, crypt hyperplasia, mucosal disorganization, and reduced expression of TJ proteins, facilitating endotoxin translocation and hepatic immune activation [51, 52]. DAM not only restored mucosal architecture but also significantly upregulated Claudin-1, ZO-1, and Occludin expression, thereby reinforcing epithelial junctions and reducing intestinal permeability. This barrier-protective effect suggests that DAM disrupts the cycle of endotoxin leakage and hepatic inflammation, representing a key mechanism of its systemic anti-fibrotic action. Compared with other natural products, DAM exhibits unique pharmacological characteristics. Flavonoids such as apigenin primarily exert anti-fibrotic effects through antioxidative activity and inhibition of the TGF-β/Smad pathway, whereas lignans such as phillygenin possess stronger anti-inflammatory and microbiota-modulating properties [20, 21]. In contrast, DAM displayed a multi-targeted profile centered on the gut-liver axis, simultaneously reshaping microbial composition, reducing endotoxin burden, and repairing intestinal barrier integrity. This “multi-pathway, systemic intervention” may represent a key advantage that differentiates DAM from other compounds and highlights its translational potential. Nevertheless, this study has several limitations. Functional insights into microbial alterations were primarily inferred from taxonomic abundance and existing literature, lacking direct metabolomic validation. Whether SCFAs, secondary bile acids, or other microbial metabolites mediate DAM’s protective effects remains to be established. Future studies integrating targeted and untargeted metabolomics, transcriptomics, and fecal microbiota transplantation will be essential to clarify the metabolic underpinnings of DAM activity and provide a more comprehensive understanding of its impact on gut–liver axis homeostasis. Moreover, the translation of these preclinical findings to human liver fibrosis requires further validation in additional animal models and clinical studies. In view of the above findings, we propose a possible mechanism by which DAM ameliorates CCl4-induced liver fibrosis (Fig. 11). DAM exerts its protective effects against liver fibrosis by inhibiting inflammation and modulating gut microbiota composition, thereby restoring intestinal barrier integrity and suppressing HSC activation. These findings identify DAM as a promising candidate for anti-fibrotic therapy and provide a foundation for further mechanistic and translational research. The potential mechanism of DAM in ameliorating CCl4-induced liver fibrosis Conclusions In summary, this study demonstrates that DAM significantly ameliorates CCl4-induced liver fibrosis in mice. It exerts its anti-fibrotic effects through multiple mechanisms, including inhibiting hepatic inflammation, suppressing of HSC activation, modulating gut microbiota composition, restoring intestinal barrier integrity and reducing of systemic endotoxemia. These findings highlight the therapeutic potential of DAM as a novel candidate for the treatment of liver fibrosis. Further studies are needed to elucidate its precise molecular targets and evaluate its clinical translational value. Abbreviations Alanine aminotransferase Aspartate aminotransferase Carbon tetrachloride Deacetylasperulosidic acid methyl ester Extracellular matrix Firmicutes-to-Bacteroidota Hyaluronic acid Hepatocellular carcinoma Hematoxylin and eosin Hepatic stellate cells Type IV collagen Linear discriminant analysis Laminin Lipopolysaccharides Non-metric multidimensional scaling Principal component analysis Procollagen type III Partial least squares discriminant analysis Redundancy analysis Real-time quantitative PCR Short-chain fatty acids α-Smooth muscle actin γ-Glutamyl transpeptidase Author Contribution Li Chen: project administration, writing-original draft. Chunyan Chen and Qixiang Chen: writing-reviewing and editing. Ting Jiang: data curation, writing-original draft. Lingli Zheng: validation. Rong Tang: writing-reviewing and editing, visualization. Cheng Wang: methodology, conceptualization, writing-reviewing and editing, funding acquisition. All authors read and approved the final manuscript. Funding This study was supported by the Chengdu Medical College Research Program (No. CYZYB24-20), the High-Level Scientific Research Start-up Fund of the First Affiliated Hospital of Chengdu Medical College (No. CYFY-GQ77), and the Institute of Pharmaceutical Research of Chengdu Medical College (No. 25LHYW2-03). Data Availability No datasets were generated or analysed during the current study. Declarations Ethics Approval All experimental procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals of Chengdu Medical College and approved by the Institutional Animal Care and Use Committee of Chengdu Medical College. Consent for Publication All authors have read the manuscript and authorized its publication. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Li Chen, Chunyan Chen and Qixiang Chen have contributed equally to this work. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.